Citations

Showing 10 of 108094 citations.

Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning
Eaton, John E. , Vesterhus, Mette , McCauley, Bryan M. , Atkinson, Elizabeth J. , Schlicht, Erik M., Juran, Brian D., Gossard, Andrea A., Karlsen, Tom H. , Lazaridis, Konstantinos N. , LaRusso, Nicholas F. , Gores, Gregory J.

Mayo Clinic

Hepatology | May 9, 2018 | Volume: 71 | Issue: 1 | Pages: 214-224

10.1002/hep.30085 | PMID 29742811 Get It

Improved methods are needed to risk stratify and predict outcomes in patients with primary sclerosing cholangitis (PSC). Therefore, we sought to derive and validate a prediction model and compare its performance to existing surrogate markers. The model was derived using 509 subjects from a multicenter North American cohort and validated in an international multicenter cohort (n = 278). Gradient boosting, a machine‐based learning technique, was used to create the model. The endpoint was hepatic decompensation (ascites, variceal hemorrhage, or encephalopathy). Subjects with advanced PSC or cholangiocarcinoma (CCA) at baseline were excluded. The PSC risk estimate tool (PREsTo) consists of nine variables: bilirubin, albumin, serum alkaline phosphatase (SAP) times the upper limit of normal (ULN), platelets, aspartate aminotransferase (AST), hemoglobin, sodium, patient age, and number of years since PSC was diagnosed. Validation in an independent cohort confirms that PREsTo accurately predicts decompensation (C‐statistic, 0.90; 95% confidence interval [CI], 0.84‐0.95) and performed well compared to Model for End‐Stage Liver Disease (MELD) score (C‐statistic, 0.72; 95% CI, 0.57‐0.84), Mayo PSC risk score (C‐statistic, 0.85; 95% CI, 0.77‐0.92), and SAP <1.5 × ULN (C‐statistic, 0.65; 95% CI, 0.55‐0.73). PREsTo continued to be accurate among individuals with a bilirubin <2.0 mg/dL (C‐statistic, 0.90; 95% CI, 0.82‐0.96) and when the score was reapplied at a later course in the disease (C‐statistic, 0.82; 95% CI, 0.64‐0.95). Conclusion: PREsTo accurately predicts hepatic decompensation (HD) in PSC and exceeds the performance among other widely available, noninvasive prognostic scoring systems.
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Kumar, Shaji , Durie, Brian G.M. , Nahi, Hareth , Vij, Ravi , Kastritis, Efstathios , Terpos, Evangelos , Leleu, Xavier , Beksaç, Meral , Goldschmidt, Hartmut , Hillengaß, Jens , Khan, Imran , Lam, Annette , Beksaç, Meral , Terpos, Evangelos , Kastritis, Efstathios , Beksac, Meral , Dimopoulos, Meletios Α. , Su, Zhuo T. , Hutton, Brian F. , Cameron, Chris G , Nahi, Hareth

Mayo Clinic

Leukemia & Lymphoma | May 9, 2018 | Volume: 60 | Issue: 1 | Pages: 163-171

10.1080/10428194.2018.1459609 | PMID 29741423 Get It

Emergency Department Telepsychiatry Service Model for a Rural Regional Health System: The First Steps
Meyer, James D., McKean, Alastair J. , Blegen, Rebecca N., McKean, Alastair J S, Demaerschalk, Bart M.

Mayo Clinic

Telemedicine and e-Health | May 9, 2018 | Volume: 25 | Issue: 1 | Pages: 18-24

10.1089/tmj.2017.0293 | PMID 29742036 Get It

Background: Emergency departments (EDs) have recognized an increasing number of patients presenting with mental health (MH) concerns. This trend imposes greater demands upon EDs already operating at capacity. Many ED providers do not feel they are optimally prepared to provide the necessary MH care. One consideration in response to this dilemma is to use advanced telemedicine technology for psychiatric consultation. Introduction: We examined a rural- and community-based health system operating 21 EDs, none of which has direct access to psychiatric consultation. Dedicated beds to MH range from zero (in EDs with only 3 beds) to 6 (in an ED with 38 beds). Materials and Methods: We conducted a needs assessment of this health system. This included a survey of emergency room providers with a 67% response rate and site visits to directly observe patient flow and communication with ED staff. A visioning workshop provided input from ED staff. Data were also obtained, which reflected ED admissions for the year 2015. Results: The data provide a summary of provider concerns, a summary of MH presentations and diagnosis, and age groupings. The data also provide a time when most MH concerns present to the ED. Discussion: Based upon these results, a proposed model for delivering comprehensive regional emergency telepsychiatry and behavioral health services is proposed. Conclusions: Emergency telepsychiatry services may be a tenable solution for addressing the shortage of psychiatric consultation to EDs in light of increasing demand for MH treatment in the ED.
Human skills for human[istic] anatomy: An emphasis on nontraditional discipline‐independent skills
Evans, Darrell J. R. , Pawlina, Wojciech, Lachman, Nirusha , Evans, D

Mayo Clinic

Anatomical Sciences Education | May 9, 2018 | Volume: 11 | Issue: 3 | Pages: 221-224

10.1002/ase.1799 | PMID 29742329 Get It

Updates in the Care of Women During Menopause
Kransdorf, Lisa N. , Files, Julia A. , Kransdorf, Lisa N

Mayo Clinic

Journal of Women's Health | May 9, 2018 | Volume: 27 | Issue: 6 | Pages: 744-747

10.1089/jwh.2018.7082 | PMID 29741981 Get It

Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint
Lacy, Brian E. , Nicandro, Jean Paul, Chuang, Emil , Earnest, David L.

Mayo Clinic

Therapeutic Advances in Gastroenterology | May 9, 2018 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1756284818771674 | PMID 29774051 Get It

Background: Alosetron is approved to treat women with severe IBS and diarrhea (IBS-D) who have failed standard therapy. In our study, we aimed to evaluate alosetron efficacy using new US Food and Drug Administration (FDA) endpoints and utilization in clinical practice. Methods: This prospective, open-label, multicenter, observational 12-week study evaluated women with severe IBS-D enrolled in the alosetron prescribing program. The coprimary FDA endpoints were changes from baseline in stool consistency and abdominal pain severity. Responders achieved a 30% decrease compared with baseline in weekly average of the worst abdominal pain in the past 24 h, and a 50% or greater reduction from baseline in the number of days/week with at least one stool of type 6 (mushy) or type 7 (watery) consistency. Secondary endpoints included changes from baseline in stool frequency, fecal urgency and fecal incontinence. Results: Enrolled patients ( n = 192) were primarily White (90.6%), with a mean age of 44.5 years. Patient and physician rating of IBS severity was between moderate and severe (85.9% concordance, Spearman coefficient 0.429, p < 0.0001). Alosetron 0.5 mg twice daily (82.8%) was the most common dosing regimen. A total of 152 alosetron-treated patients completed the study. Of 105 fully evaluable patients, 45% met the FDA composite endpoint responder criteria for ⩾50% of the study period. Improvements in all individual symptoms were statistically significant compared with baseline. There were no serious adverse events, cases of colonic ischemia, or complications of constipation. Conclusion: In a clinical practice setting study, alosetron demonstrated treatment success using a rigorous FDA composite endpoint and also improved multiple other IBS symptoms, including fecal urgency and incontinence in women with severe IBS-D [ ClinicalTrials.gov identifier: NCT01257477].
Return on investment for financial assistance for living kidney donors in the United States
Mathur, Amit K. , Xing, Jiawei, Dickinson, David M., Warren, Patricia H., Ojo, Akinlolu , Merion, Robert M. , Gifford, Kimberly A. , Hong, Barry A.

Mayo Clinic

Clinical Transplantation | May 9, 2018 | Volume: 32 | Issue: 7 | Pages: No page available

10.1111/ctr.13277 | PMID 29740879 Get It

AbstractBackgroundThe National Living Donor Assistance Center (NLDAC) enables living donor kidney transplants through financial assistance of living donors, but its return on investment (ROI) through savings on dialysis costs remains unknown.MethodsWe retrospectively reviewed 2012‐2015 data from NLDAC, the United States Renal Data System, and the Scientific Registry of Transplant Recipients to construct 1‐, 3‐, and 5‐year ROI models based on NLDAC applications and national dialysis and transplant cost data. ROI was defined as state‐specific federal dialysis cost minus (NLDAC program costs plus state‐specific transplant cost), adjusted for median waiting time (WT).ResultsA total of 2425 NLDAC applications were approved, and NLDAC costs were USD $6.76 million. Median donor age was 41 years, 66.1% were female, and median income was $33 759; 43.6% were evaluated at centers with WT >72 months. Median dialysis cost/patient‐year was $81 485 (IQR $74 489‐$89 802). Median kidney transplant cost/patient‐year was $30 101 (IQR $26 832‐$33 916). Overall, ROI varied from 5.1‐fold (1‐year) to 28.2‐fold (5‐year), resulting in $256 million in savings. Higher ROI was significantly associated with high WT, larger dialysis and transplant costs differences, and more NLDAC applicants completing the donation process.ConclusionsFinancial support for donor out‐of‐pocket expenses produces dramatic federal savings through incremental living donor kidney transplants.
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials
Iwatsubo, Takeshi , Iwata, Atsushi , Suzuki, Kazushi , Ihara, Ryoko , Arai, Hiroyuki , Ishii, Kenji , Senda, Michio , Kuwano, Ryozo, Initiative, Japanese Alzheimer's Disease Neuroimaging, Sun, Chung‐Kai , Petersen, Ronald C. , Weiner, Michael W. , Aisen, Paul , Donohue, Michael , Initiative, Alzheimer's Disease Neuroimaging, Shoji, Mikio , Ito, Kengo , Ikeuchi, Takeshi , Matsuda, Hiroshi , Initiative, Japanese Alzheimer's Disease Neuroimaging, Beckett, Laurel , Initiative, Alzheimer's Disease Neuroimaging, Donohue, Michael C

Mayo Clinic

Alzheimer's & Dementia | May 9, 2018 | Volume: 14 | Issue: 8 | Pages: 1077-1087

10.1016/j.jalz.2018.03.009 | PMID 29753531 Get It

AbstractIntroductionWe conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J‐ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America.MethodsA total of 537 Japanese subjects with normal cognition, late amnestic mild cognitive impairment (LMCI), or mild Alzheimer's disease (AD) were enrolled using the same criteria as ADNI. Rates of changes in representative cognitive or functional measures were compared for amyloid positron emission tomography‐ or cerebrospinal fluid amyloid β(1–42)‐positive LMCI and mild AD between J‐ADNI and ADNI.ResultsAmyloid positivity rates were significantly higher in normal cognition of ADNI but at similar levels in LMCI and mild AD between J‐ADNI and ADNI. Profiles of decline in cognitive or functional measures in amyloid‐positive LMCI in J‐ADNI (n = 75) and ADNI (n = 269) were remarkably similar, whereas those in mild AD were milder in J‐ADNI (n = 73) compared with ADNI (n = 230).DiscussionThese results support the feasibility of bridging of clinical trials in the prodromal stage of AD between Asia and western countries.
Prostatic collagen architecture in neutered and intact canines
Ruetten, Hannah , Wegner, Kyle A. , Romero, Michael F. , Wood, Michael W. , Marker, Paul C. , Strand, Douglas W. , Colopy, Sara A., Vezina, Chad M. , Strand, Douglas , Romero, Michael F , Vezina, Chad M

Mayo Clinic

The Prostate | May 9, 2018 | Volume: 78 | Issue: 11 | Pages: 839-848

10.1002/pros.23641 | PMID 29740846 Get It

BackgroundProstate stiffness and increased collagen content both associate with the presence of urinary symptoms in men but mechanisms responsible, including impact of age and androgens, are unknown. Dogs develop prostate‐related urinary dysfunction similar to humans, but mechanisms are also unknown. Mice have been used to examine how prostatic collagen accumulation affects voiding but whether mouse prostatic collagen organization resembles human or dog has not been evaluated. Here, we have constructed the first comprehensive, comparative maps of collagen architecture in canine, human, and mouse prostate and test whether canine prostatic collagen content is increased by aging and reduced by castration.MethodsComplete transverse prostate sections were stained with picrosirius red and imaged with confocal microscopy to reveal and compare collagen architecture across species. Canine prostatic collagen fiber length, diameter, and density in prostatic urethral, periurethral, peripheral, and capsular regions were quantified and compared among four experimental groups: young intact, young neutered, old intact, and old neutered dogs.ResultsSurprisingly, the majority of collagen was localized to the prostatic urethra in canine, human, and mouse. In canine and human, capsular regions also featured a dense collagen network but it appeared less dense than around prostatic urethra. Older, intact male canines exhibited overall denser prostate collagen fibers and had thicker capsular fibers than young, intact males. Prostatic glandular regions undergo dramatic atrophy and regression following castration, and our finding of neutered animals having increased collagen fiber density in both periurethral and peripheral regions is consistent with glandular contraction and increased proportion of stroma.ConclusionsCollagen architecture in dog appears similar to that in humans when cross sections are compared side‐by‐side. Canine collagen organization is affected by both age and androgen status, suggesting these factors may contribute to collagen accumulation in some males.
Collaborative Care Management Associated With Improved Depression Outcomes in Patients With Personality Disorders, Compared to Usual Primary Care
Solberg, Jeremy J., Deyo-Svendsen, Mark , Nylander, Kelsey R., Bruhl, Elliot J., Heredia, Dagoberto , Angstman, Kurt B. , Deyo-Svendsen, Mark E, Angstman, Kurt B

Mayo Clinic

Journal of Primary Care & Community Health | May 9, 2018 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/2150132718773266 | PMID 29739287 Get It

Background: The use of a collaborative care management (CCM) model can dramatically improve short- and long-term treatment outcomes for patients with major depressive disorder (MDD). Patients with comorbid personality disorder (PD) may experience poorer treatment outcomes for MDD. Our study seeks to examine the differences in MDD treatment outcomes for patients with comorbid PD when using a CCM approach rather than usual care (UC). Methods: In our retrospective cohort study, we reviewed the records of 9614 adult patients enrolled in our depression registry with the clinical diagnosis MDD and the diagnosis of PD (Yes/No). Clinical outcomes for depression were measured with Patient Health Questionnaire–9 (PHQ-9) scores at 6 months. Results: In our study cohort, 59.4% of patients (7.1% of which had comorbid PD) were treated with CCM, as compared with 40.6% (6.8% with PD) treated with UC. We found that the presence of a PD adversely affected clinical outcomes of remission within both groups, however, at 6 months patients with PD had significantly lower MDD remission rates when treated with UC as compared with those treated with CCM (11.5% vs 25.2%, P = .002). Patients with PD in the UC group were also noted to have an increased rate of persistent depressive symptoms (PHQ-9 score ≥10) at 6 months as compared with those in the CCM group (67.7% vs 51.7%, P = .004). Conclusions: In patients with comorbid MDD and PD, clinical outcomes at 6 months were significantly improved when treated with CCM compared with UC. This finding is encouraging and supports the idea that CCM is an effective model for caring for patients with behavioral concerns, and it may be of even greater benefit for those patients being treated for comorbid behavioral health conditions.